<DOC>
	<DOCNO>NCT00631410</DOCNO>
	<brief_summary>To assess safety tolerability sunitinib administer combination modify FOLFOX6 Japanese patient metastatic colorectal cancer first-line treatment setting .</brief_summary>
	<brief_title>Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma colon rectum document locally advanced metastatic disease . Evidence unidimensionally measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Prior treatment systemic therapy locally advance metastatic colorectal cancer . Prior surgery investigational agent within 4 week prior study entry . Pregnancy breastfeed . All female patient reproductive potential must negative pregnancy test ( serum urine ) prior start study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>CRC</keyword>
	<keyword>SU011248</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>FOLFOX</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>metastatic carcinoma colon rectum</keyword>
</DOC>